Insilico Medicine announced the design of novel pan-KRAS inhibitors through its Chemistry42 AI platform, overcoming challenges associated with KRAS’ undruggable nature. Utilizing structure-based drug design and scaffold hopping, researchers generated diverse chemotypes displaying nanomolar potency against multiple KRAS mutants. This advancement represents a critical juncture in cancer therapeutics, potentially broadening the scope of targeted treatments for KRAS-driven malignancies.